Organic growth of 8.3% for the Bastide Group in the first quarter of 2025-2026

The Bastide Group posted a strong performance for the first quarter of fiscal year 2025-2026, with revenue of €126.3 million, representing organic growth of 8.3%. Home healthcare services, accounting for 61.3% of revenue, increased by 10.7%, despite a price reduction for sleep apnea. The "Home Care" business also saw a 4.7% increase, driven by strong demand from local authorities.

The respiratory segment recorded organic growth of 11.7%, driven by strong performance in France and internationally. The "Nutrition-Perfusion-Diabetes-Stoma Therapy" division grew by 9.5%, thanks to the expansion of the diabetes segment and the recovery of the stoma therapy business.

For the 2025-2026 financial year, Bastide is aiming for a turnover of at least 510 million euros, despite forecasts of a further price reduction in April 2026.